Write in a clean editor, then format for Frontiers in Drug Discovery in one click — DocuGuru applies the official Frontiers template with author–year references and exports a submission-ready PDF plus the editable LaTeX source. Free to start.
Frontiers in Drug Discovery is a peer-reviewed journal published by Frontiers, covering Computational Drug Discovery Methods, SARS-CoV-2 and COVID-19 Research, vaccines and immunoinformatics approaches. Over its lifetime it has published 196 papers, which have received 1,673 citations.
| Publisher | Frontiers |
|---|---|
| Reference style | Author–year (Harvard) Author–year — (Smith, 2023) in the text Smith, A., Jones, B. and Lee, C. (2023) 'A representative article title', Frontiers in Drug Discovery, 12(3), pp. 45–58.
Formats any DOI in Frontiers in Drug Discovery style. No sign-up. |
| Publishes research in | Computational Drug Discovery Methods SARS-CoV-2 and COVID-19 Research vaccines and immunoinformatics approaches Monoclonal and Polyclonal Antibodies Research Microbial Natural Products and Biosynthesis |
| ISSN | 2674-0338 |
| Citation impact (2-yr) | 6.25 |
| h-index | 19 |
| i10-index | 45 |
| Open access | Yes — indexed in DOAJ |
| Top institutions publishing here | Universidad Nacional Autónoma de México |
| You get | A submission-ready PDF and the editable LaTeX source — ready to submit. |
Citations each year’s papers have accumulated so far — the most recent years are still building up.
Finding new drugs usually consists of five main stages: 1) a pre-discovery stage in which basic research is performed to try to understand the mechanisms leading to diseases and propose possible targets (e.g., proteins); 2) the drug discovery stage, during which scientists search for molecules (two main large families, small molecules and biologics) or other…
In the drug discovery and development, the identification of leadcompoundsplaysa crucial role in the quest for novel therapeutic agents. Leadcompounds are the initial molecules that show promising pharmacological activity againsta specific target and serve as the foundation for drug development. Integrativecomputational approaches have emerged as powerful tools in expediting this complex andresource-intensive process. They enable…
Traditional de novo drug discovery, which typically presents an 11% approval rate from phase I trials and even higher failure rates in fields like neurodegeneration, often requires two to three billion dollars and 10–17 years per new drug. In contrast, drug repurposing can reduce risks and bring drugs to the market in 3–12 years, with…
Animals like mice and rats have long been used in medical research to help understand disease and test potential new treatments before human trials. However, while animal studies have contributed to important advances, too much reliance on animal models can also mislead drug development. This article explains for a general audience how animal research is…
Over 90% of marketed drugs are small molecules, low molecular weight organic compounds that have been discovered, designed, and developed to prompt a specific biological process in the body. Examples include antibiotics (penicillin), analgesics (paracetamol) and synthetic hormones (corticosteroids). On average, it takes 10–15 years to develop a new medicine from initial discovery through to…
